Drugs / cipargamin
cipargamin
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04321252 | Jul → Nov 2020 | malaria | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02543086 | Jul → Sep 2015 | Plasmodium falciparum malaria | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT07235033 | Jan 2024 → Mar 2025 | Plasmodium falciparum malaria | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT05750628 | Jan 2024 → Jun 2026 overdue | Plasmodium falciparum malaria | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 2 | NCT04675931 | Mar 2022 → Jul 2025 | Plasmodium falciparum malaria | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03334747 | Nov 2017 → Nov 2019 | malaria | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01836458 | Jan 2014 → Mar 2015 | malaria | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01860989 | Jul 2013 → Aug 2014 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01524341 | Jan → Jun 2012 | malaria | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cipargamin | “This first-in-human study assessed safety, tolerability, and pharmacokinetics (PK) of cipargamin (intravenous) in healthy adults.” PMID 39058022 ↗ Jul 20244“the new antimalarial cipargamin (KAE609) in adults with uncomplicated Plasmodium falciparum malaria” PMID 27872070 ↗ Jan 2017 “KAE609 (cipargamin; formerly NITD609, Novartis Institute for Tropical Diseases)” PMID 25075833 ↗ Jul 2014 “oral KAE609 (Cipargamin)” NCT05750628 ↗ |
| Known as | Cipargamina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1082723 ↗ |
| Known as | Cipargamine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1082723 ↗ |
| Known as | KAE609 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01860989 ↗ |
| Known as | NITD609 | “KAE609 (cipargamin; formerly NITD609, Novartis Institute for Tropical Diseases)” PMID 25075833 ↗ Jul 2014 |
| Modality | Small molecule | “is a new synthetic antimalarial spiroindolone analogue” PMID 25075833 ↗ Jul 2014 |
| Route | Oral | “KAE609 was supplied as capsules for oral use.” NCT01524341 ↗ |